The mucopolysaccharidoses (MPS) comprise a heterogeneous family of rare, genetic lysosomal storage disorders
that result in severe morbidity and reduced life expectancy. Emerging treatments for several of these disorders have
triggered the search for clinically relevant biomarkers and clinical markers associated with treatment efficacy in
populations and individuals. However, biomedical measures do not tell the whole story when characterizing a
complex chronic disorder such as MPS. Health-related quality of life (HRQoL) tools that utilize patient reported
outcomes to address patient parameters such as symptoms (pain, fatigue, psychological health), functioning
(activity and limitations), or quality of life, have been used to supplement traditional biomedical endpoints. Many of
these HRQoL tools have demonstrated that quality of life is negatively impacted in patients with MPS. There is both
the opportunity and need to formally standardize and validate HRQoL tools for the different MPS disorders.
Additional file 1: Table S1. Classification of MPS.
Additional file 2: Patient-reported outcome (PRO) measures used in
mucopolysaccharidosis (MPS) studies.